WATERTOWN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced ...
Abata Therapeutics Inc. has selected its first development candidate, ABA-101, an autologous regulatory T cell (Treg) therapy for the treatment of progressive multiple sclerosis (MS). ABA-101 targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results